Bristol-Myers Squibb Co (NYSE:BMY) Shares Sold by Lipe & Dalton

Lipe & Dalton trimmed its position in shares of Bristol-Myers Squibb Co (NYSE:BMY) by 0.5% during the second quarter, Holdings Channel reports. The firm owned 73,096 shares of the biopharmaceutical company’s stock after selling 353 shares during the quarter. Bristol-Myers Squibb makes up approximately 2.4% of Lipe & Dalton’s portfolio, making the stock its 15th biggest holding. Lipe & Dalton’s holdings in Bristol-Myers Squibb were worth $3,315,000 at the end of the most recent quarter.

A number of other large investors have also recently added to or reduced their stakes in BMY. James Investment Research Inc. raised its stake in shares of Bristol-Myers Squibb by 36.5% in the first quarter. James Investment Research Inc. now owns 819 shares of the biopharmaceutical company’s stock valued at $39,000 after acquiring an additional 219 shares in the last quarter. Lowe Brockenbrough & Co. Inc. increased its holdings in Bristol-Myers Squibb by 0.5% in the first quarter. Lowe Brockenbrough & Co. Inc. now owns 43,384 shares of the biopharmaceutical company’s stock valued at $2,070,000 after buying an additional 220 shares during the last quarter. Squar Milner Financial Services LLC increased its holdings in Bristol-Myers Squibb by 5.6% in the first quarter. Squar Milner Financial Services LLC now owns 4,209 shares of the biopharmaceutical company’s stock valued at $200,000 after buying an additional 223 shares during the last quarter. Modera Wealth Management LLC increased its holdings in Bristol-Myers Squibb by 4.3% in the fourth quarter. Modera Wealth Management LLC now owns 5,567 shares of the biopharmaceutical company’s stock valued at $289,000 after buying an additional 229 shares during the last quarter. Finally, Clear Harbor Asset Management LLC increased its holdings in Bristol-Myers Squibb by 2.4% in the first quarter. Clear Harbor Asset Management LLC now owns 9,637 shares of the biopharmaceutical company’s stock valued at $460,000 after buying an additional 229 shares during the last quarter. Institutional investors own 77.60% of the company’s stock.

Shares of BMY stock opened at $45.99 on Friday. The business’s 50-day moving average price is $45.66. The stock has a market capitalization of $72.64 billion, a price-to-earnings ratio of 11.56, a price-to-earnings-growth ratio of 2.20 and a beta of 0.73. Bristol-Myers Squibb Co has a 1 year low of $42.48 and a 1 year high of $63.69. The company has a debt-to-equity ratio of 1.51, a quick ratio of 3.75 and a current ratio of 3.88.

Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings data on Thursday, July 25th. The biopharmaceutical company reported $1.18 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.06 by $0.12. The company had revenue of $6.27 billion for the quarter, compared to analyst estimates of $6.10 billion. Bristol-Myers Squibb had a return on equity of 47.63% and a net margin of 26.14%. The business’s quarterly revenue was up 10.0% compared to the same quarter last year. During the same quarter last year, the company posted $1.01 earnings per share. On average, research analysts forecast that Bristol-Myers Squibb Co will post 4.26 EPS for the current fiscal year.

The company also recently disclosed a quarterly dividend, which was paid on Thursday, August 1st. Shareholders of record on Friday, July 5th were issued a dividend of $0.41 per share. This represents a $1.64 annualized dividend and a dividend yield of 3.57%. The ex-dividend date of this dividend was Wednesday, July 3rd. Bristol-Myers Squibb’s payout ratio is 41.21%.

In other news, Director Theodore R. Samuels II acquired 5,000 shares of the company’s stock in a transaction on Thursday, May 16th. The shares were bought at an average price of $47.29 per share, with a total value of $236,450.00. Following the completion of the acquisition, the director now owns 27,000 shares in the company, valued at approximately $1,276,830. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider Karen Murphy Santiago sold 3,065 shares of the firm’s stock in a transaction dated Thursday, May 16th. The stock was sold at an average price of $47.56, for a total value of $145,771.40. Following the transaction, the insider now directly owns 3,066 shares in the company, valued at approximately $145,818.96. The disclosure for this sale can be found here. Company insiders own 0.13% of the company’s stock.

Several equities analysts recently commented on the company. BMO Capital Markets increased their target price on Bristol-Myers Squibb from $62.00 to $63.00 and gave the company an “outperform” rating in a report on Wednesday, April 17th. Argus lowered Bristol-Myers Squibb from a “buy” rating to a “hold” rating and set a $46.36 target price on the stock. in a report on Monday, May 20th. Goldman Sachs Group assumed coverage on Bristol-Myers Squibb in a report on Tuesday, May 28th. They issued a “buy” rating and a $54.00 target price on the stock. Zacks Investment Research raised Bristol-Myers Squibb from a “hold” rating to a “buy” rating and set a $54.00 target price on the stock in a report on Tuesday, May 7th. Finally, JPMorgan Chase & Co. assumed coverage on Bristol-Myers Squibb in a report on Friday, May 3rd. They issued an “overweight” rating and a $62.00 target price on the stock. One investment analyst has rated the stock with a sell rating, nine have issued a hold rating and eight have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus target price of $55.45.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers drugs in oncology, immunoscience, cardiovascular, and fibrotic diseases. The company's products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with moderately to severely active RA and prostate-specific antigen, as well as reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis.

Further Reading: How do buyers and sellers choose a strike price?

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.